| |
Home > Healthcare
> Drugs & Biotech
The latest headlines and interview extracts:
Analyst recommends AVI BioPharma (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology
Analyst says Geron has cancer vaccine data coming up that could move the stock significantly (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology
CEO of Pharming Group discusses progress of lead product for hereditary angioedema (6/3/03)
- FRANCIS PINTO, Pharming Group
- Biotechnology
CEO of Alltracel Pharmaceuticals discusses strategy and opportunities for stops-bleeding products in wound care market (6/3/03)
- GERARD BRANDON, Alltracel Pharmaceuticals
- Pharmaceuticals
CE of Oxford BioMedica discusses progress of two lead cancer products (5/7/03)
- ALAN KINGSMAN, Oxford BioMedica PLC
- Biotechnology
CEO of Provalis plc says diabetes diagnostic product, Glycosal, has done extremely well in the States during first six months (5/7/03)
- PHIL GOULD, Provalis plc
- Biotechnology
President & CEO of Compugen Ltd. talks about potential long-term large revenues from licensing of in-house discoveries (5/1/03)
- DR. MOR AMITAI, Compugen Ltd.
- Biotechnology
Executive Chairman and Deputy Chairman of Mologen AG discuss product pipeline and strategic goals (3/17/03)
- BURGHARDT WITTIG & GUIDO SANDLER, Mologen Holding AG
- Biotechnology
CEO of Girindus AG outlines key strengths and objectives in pre-NDA niche (2/19/03)
- FRITZ LINK, Girindus AG
- Pharmaceuticals
CEO of Maelor Plc discusses product pipeline and opportunities to exploit current products beyond UK market (2/19/03)
- STEPHEN APPELBEE, Maelor PLC
- Pharmaceuticals
Company Interview Excerpt: Jean Archambault - Phytobiotech Inc (1/27/03)
- Jean Archambault, Phytobiotech Inc
- Biotechnology
Analyst has high hopes for Avigen (10/18/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology
Analyst is encouraged by recent move from AstraZeneca (10/17/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology
Shire is a winner with analyst (8/30/02)
- DAVID M. STEINBERG, CIBC World Markets
- Pharmaceuticals
Analyst highlights Teva as top pick based on strength of proprietary product (8/28/02)
- MARIA LEGATOS-PHILLIPS, Banc of America Securities
- Pharmaceuticals
Analyst cites Mylan as great long-term buy (8/28/02)
- RODNEY C. SINGL, .W. Henssler & Associates, Ltd.
- Pharmaceuticals
CEO says Fulcrum Pharm PLC aims to increase services and products in Europe, U.S., and Japan (8/26/02)
- JON P. COURT, Fulcrum Pharma PLC
- Pharmaceuticals
CEO of Perbio Science discusses growing market opportunities for protein research tools (8/7/02)
- MATS FISCHIER, Perbio Science AB
- Biotechnology
CFO of Qiagen says clear leadership in tool space is very sustainable (7/31/02)
- PEER M. SCHATZ, Qiagen NV
- Biotechnology
CEO of Compugen outlines opportunities in mergering of drug discovery processes and computational technologies (7/29/02)
- DR. MOR AMITAI, Compugen Ltd.
- Biotechnology
CE of Oxford BioMedica PLC comments on strong and diverse product portfolio (7/24/02)
- PROF ALAN J KINGSMAN, Oxford BioMedica PLC
- Biotechnology
CEO of BioTissue Technologies AG discusses product pipeline and partnership opportunities in tissue (7/17/02)
- DR. VICTOR TIEGERMANN, BioTissue Technologies AG
- Biotechnology
CEO of Genemedix talks about collaboration with the Shanghai Institute of Biochemistry (7/15/02)
- PAUL EDWARDS, GeneMedix plc
- Biotechnology
CEO of MWG BIOTECH discusses turnaround and market potential (7/15/02)
- DR. MATTIAS SCHÖNERMARK, MWG-BIOTECH AG
- Biotechnology
Analyst comments on Millenium's winning hands on formula (7/10/02)
- JONATHAN ASCHOFF, PHD, Friedman, Billings, Ramsey & Co., Inc.
- Biotechnology
Company Interview Excerpt: Gualberto Ruano - Genaissance Pharmaceuticals Inc (GNSC) (7/8/02)
- Gualberto Ruano, Genaissance Pharmaceuticals Inc (GNSC)
- Biotechnology
Analyst favors IDEC Pharmaceuticals (5/24/02)
- ALBERT RAUCH, Ladenburg, Thalmann & Co.
- Biotechnology
ProMetic Life Sciences has very interesting technology, reports Analyst (5/7/02)
- CLAUDE CAMIRÉ, Dundee Securities
- Biotechnology
Company Interview Excerpt: Hans Dieter RÖSSLER - Curasan AG (549453.F) (4/10/02)
- Hans Dieter RÖSSLER, Curasan AG (549453.F)
- Pharmaceuticals
Analyst highlights Johnson & Johnson's rapamycin drug-eluding stent called CYPHER (3/22/02)
- PETER WEN, Credit Suisse Asset Management
- Pharmaceuticals
Analyst highlights Northwest Biotherapeutics (2/20/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology
Analyst is interested in Nastech (2/7/02)
- LOUIS C. WEBB, RBC Capital Markets
- Drug Delivery
Analyst believes over the next five years, Pfizer will outperform the drug group (12/6/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals
Analyst explains why he favors GlaxoSmithKline (12/5/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals
Analyst believes that American Home Products has only a moderately attractive pipeline (12/4/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals
Company Interview Excerpt: Mark Kirby - Profile Therapeutics - (PTP.L) (10/24/01)
- Mark Kirby, Profile Therapeutics - (PTP.L)
- Drug Delivery
Company Interview Excerpt: Philip Coelho - Thermogenesis Corporation (KOOL) (10/12/01)
- Philip Coelho, Thermogenesis Corporation (KOOL)
- Biotechnology
Company Interview Excerpt: Paul Freiman - Neurobiological Technologies Inc (NTII) (10/12/01)
- Paul Freiman, Neurobiological Technologies Inc (NTII)
- Biotechnology
Analyst has a strong buy on Myriad Genetics on the genomics side (10/10/01)
- RICKY GOLDWASSER, UBS Warburg LLC
- Biotechnology
Analyst highlights Collateral Therapeutics' lead product, Generx (10/5/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology
Off The Record: A Premier Biotech Analyst praises Pharmacia's CEO (10/5/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology
Analyst cites Genentech as a world-class company (10/5/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology
Analyst highlights Amgen's product, Aranesp (10/4/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology
Analyst cites MedImmune as a very successful company (10/4/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology
Off The Record: Top Industry Watcher cites InterMune as interesting (10/4/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology
Off The Record: Human Genome Science’s management is doing it quite right, a Biotech Expert reports (10/3/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology
Analyst rates ICOS as a buy-rated stock (10/3/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology
Analyst highlights Serono (10/2/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology
Company Interview Excerpt: Axel Unterbeck - Memory Pharmaceuticals Corporation (9/14/01)
- Axel Unterbeck, Memory Pharmaceuticals Corporation
- Pharmaceuticals
Company Interview Excerpt: Paul Clark - Icos Corporation (ICOS) (9/14/01)
- Paul Clark, Icos Corporation (ICOS)
- Biotechnology
Analyst expects to see acceleration in development activity around both of Alkermes' technologies (6/7/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic
Analyst states Enzon is an accelerating earnings growth story (6/6/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic
Analyst comments on Allergan (6/5/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic
Company Interview Excerpt: Joseph Rubinfeld - Supergen, Inc. (SUPG) (5/22/01)
- Joseph Rubinfeld, Supergen, Inc. (SUPG)
- Biotechnology
CEO comments on Caliper Technologies' first product line, Personal Laboratory System (5/10/01)
- DR. DANIEL L. KISNER, Caliper Technologies Corp.
- Biotechnology
CEO of Visible Genetics talks about the size potential of marketplace (5/8/01)
- RICHARD T. DALY, Visible Genetics Inc.
- Biotechnology
Analyst says Affymetrix is the leader in the micro-array marketplace (4/12/01)
- GEOFFREY HARRIS, UBS Warburg
- Biotechnology
Analyst explains why Tularik is a strong buy (3/30/01)
- CHARLES C. DUNCAN, Prudential Securities
- Biotechnology
Analyst highlights Myriad Genetics' products (3/29/01)
- CHARLES C. DUNCAN, Prudential Securities
- Biotechnology
CFO talks about the tremendous opportunity for Hollis-Eden Pharmaceuticals (2/27/01)
- DANIEL D. BURGESS, Hollis-Eden Pharmaceuticals, Inc.
- Pharmaceuticals
Off The Record: Top Analyst comments on Aviron's new flu vaccine (1/26/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Pharmaceuticals
CEO outlines reasons for investing in Bentley Pharmaceuticals (1/26/01)
- JAMES R. MURPHY, Bentley Pharmaceuticals, Inc.
- Biotechnology
Analyst calls Immunomedics a home run bid (1/25/01)
- D. LARRY SMITH, Sutro and Company
- Pharmaceuticals
ING Barings' Analyst believes Merck will continue to do well (1/25/01)
- SERGIO C. TRAVERSA, ING Barings, L.L.C.
- Pharmaceuticals
Senior Vice President reports on Inspire Pharmaceuticals' hybrid strategy regarding the commercialization of its technology (1/12/01)
- GREGORY J. MOSSINGHOFF, Inspire Pharmaceuticals, Inc.
- Biotechnology
CEO reports on Human Genome Sciences' competitive edge (1/12/01)
- DR. WILLIAM A. HASELTINE, Human Genome Sciences, Inc.
- Biotechnology
CEO comments on Gene Logic's financial situation (1/12/01)
- MARK GESSLER, Gene Logic, Inc.
- Biotechnology
Genzyme's CEO believes that Renagel will be the growth driver for the company in the next few years (1/12/01)
- HENRI TERMEER, Genzyme Corporation
- Biotechnology
CEO explains how Gemini Genomics differentiates itself from other people who are doing parallel things (1/12/01)
- DR. PAUL KELLY, Gemini Genomics Plc
- Biotechnology
CEO reports on Genaissance Pharmaceuticals' partnership with Janssen Research Foundation (1/12/01)
- DR. GUALBERTO RUAÑO, Genaissance Pharmaceuticals, Inc.
- Biotechnology
Senior Vice President explains HCA—The Healthcare Company's “patients first” philosophy (1/12/01)
- VICTOR L. CAMPBELL, HCA—The Healthcare Company
- Biotechnology
President talks about the benchmarks investors should use to judge Genzyme Biosurgery's progress (1/12/01)
- EARL M. "DUKE" COLLIER, JR., Genzyme Biosurgery
- Biotechnology
CEO outlines Pharsight's plans for potential partnerships (1/12/01)
- ARTHUR H. REIDEL, Pharsight Corp.
- Pharmaceuticals
CEO discusses the size and growth potential of the markets for Diversa Corporation (1/11/01)
- JAY M. SHORT, Diversa Corporation
- Biotechnology
EPIX Medical is planning on focusing solely on research and development, states CEO (1/11/01)
- MICHAEL D. WEBB, EPIX Medical, Inc.
- Biotechnology
CEO believes that Telik could become an interesting acquisition target (1/11/01)
- MICHAEL M. WICK, Telik, Inc.
- Biotechnology
CEO comments on MediChem’s current stock price (1/11/01)
- MICHAEL T. FLAVIN, MediChem Life Sciences, Inc.
- Biotechnology
CEO points to the greatest opportunities for Biacore over the next several years (1/11/01)
- LARS-GORAN ANDREN, Biacore International AB
- Biotechnology
Neose Technologies aims to remain in the absolute forefront of carbohydrate synthesis technology, reports CEO (1/11/01)
- STEPHEN A. ROTH, Neose Technologies, Inc.
- Biotechnology
CEO outlines the competitive environment for Esperion Therapeutics (1/11/01)
- ROGER NEWTON, Esperion Therapeutics, Inc.
- Drugs - Generic
CEO points to the single best opportunity in the near future for First Horizon Pharmaceutical (1/11/01)
- MAHENDRA G. SHAH, First Horizon Pharmaceutical Corporation
- Pharmaceuticals
CEO of Medicis Pharmaceutical speaks about the trends in cosmetic dermatology (1/11/01)
- Medicis Pharmaceutical Corp., Medicis Pharmaceutical Corp
- Pharmaceuticals
CEO reports on Large Scale Biology's good track record with both organic growth and acquisitions (1/11/01)
- ROBERT L. ERWIN, Large Scale Biology Corporation
- Biotechnology
CEO looks at the competition for Angiotech Pharmaceuticals (1/11/01)
- WILLIAM L. HUNTER, Angiotech Pharmaceuticals, Inc.
- Pharmaceuticals
CEO praises Vertex Pharmaceuticals' scientific and business team (1/11/01)
- DR. JOSHUA BOGER, Vertex Pharmaceuticals, Inc.
- Pharmaceuticals
CEO believes that Molecular Devices can continue to expand its lead in providing innovative technology for drug discovery research (1/11/01)
- JOSEPH D. KEEGAN, Molecular Devices Corp.
- Biotechnology
CEO gives an assessment of The Medicines Company's management team (1/11/01)
- CLIVE A. MEANWELL, The Medicines Company
- Pharmaceuticals
CEO reports on the significant advantages of SangStat Medical's RDP58 over existing TNF-alpha inhibitors (1/11/01)
- JEAN-JACQUES BIENAIMÉ, SangStat Medical Corp.
- Biotechnology
CEO commends both the management team and the scientific team at Vion Pharmaceuticals (1/11/01)
- ALAN KESSMAN, Vion Pharmaceuticals, Inc.
- Pharmaceuticals
CEO reports on DURECT's lead product: DUROS sufentanil (1/11/01)
- JAMES BROWN, DURECT Corp.
- Drug Related Products
CEO reports on the management team at Versicos (1/11/01)
- GEORGE F. HORNER, III, Versicos, Inc.
- Biotechnology
Chronimed's focus is on providing mail order and retail-based pharmacies, reports CEO (1/11/01)
- HENRY F. BLISSENBACH, Chronimed, Inc.
- Pharmaceuticals
CEO comments on PAREXEL International's current stock price (1/11/01)
- JOSEF H. VON RICKENBACH, PAREXEL International Corp.
- Pharmaceuticals
Medarex will continue to look for opportunities to acquire complementary technologies, reports CEO (1/11/01)
- DONALD L. DRAKEMAN, Medarex, Inc.
- Biotechnology
3-Dimensional Pharmaceuticals' strategy is to license out whatever the company develops, states CEO (1/11/01)
- DAVID C. U’PRICHARD, 3-Dimensional Pharmaceuticals, Inc.
- Biotechnology
Valentis' goal is to continue to have the broadest array of delivery technologies for biopharmaceuticals in the industry, reports (1/11/01)
- BENJAMIN F. MCGRAW III, Valentis, Inc.
- Biotechnology
Tularik's goal is to submit one to two IND applications per year, reports CEO (1/11/01)
- ANDREW J. PERLMAN, Tularik, Inc.
- Biotechnology
CEO comments on Biogen's current stock price (1/11/01)
- JAMES C. MULLEN, Biogen, Inc.
- Biotechnology
President is proud of Caremark Rx' financial ratios (1/11/01)
- JAMES H. DICKERSON, JR., Caremark Rx, Inc.
- Pharmaceuticals
CEO outlines QIAGEN's sales and marketing strategies (1/11/01)
- DR. METIN COLPAN, QIAGEN
- Biotechnology
For more information call (212) 952 7400. The Wall Street Transcript does
not endorse any of the comments made by interviewees, and does not make stock
recommendations.
Copyright 2000, Wall Street Transcript Corp.
|
|